Company

Bank

Analyst

Coverage

Opinion

Wk chg

9/13 cls

Advanced Cell Technology Inc. (OTCBB:ACTC)

Maxim Group

Jason Kolbert

New

Buy

7%

$0.06

Kolbert initiated coverage with a $0.45 target on the belief that Advanced Cell Technology is "ready to re-emerge as a new company, now with a high value maturing program in the macular degeneration space." Kolbert said the company hit a significant clinical milestone in July, when an independent DSMB recommended continuation of enrollment in Phase I/II trial evaluating the company's human embryonic stem cell-derived retinal pigment epithelium (RPE) cells to treat age-related macular degeneration (AMD). Kolbert models a partnership deal for RPE in 2015 with an upfront payment and royalties.

Cyclacel Pharmaceuticals Inc. (NASDAQ:CYCC)

Janney Capital Markets

Kimberly Lee

New

Buy

13%

$3.48

Lee initiated coverage with a $10 target on the view that Cyclacel's lead compound sapacitabine could be a viable oral alternative to chemotherapy for elderly patients with acute myelogenous leukemia (AML). She also views the cell cycle modulating nucleoside analog as a "pipeline within a single drug," as it has shown promising data for use in treating myelodysplastic syndrome (MDS) and various solid tumors. This half, Lee expects a DSMB review of the ongoing Phase III SEAMLESS trial with sapacitabine in AML. She projects $415M in global sales of sapacitabine in elderly AML patients by 2021. Cyclacel has rights to sapacitabine from Daiichi Sankyo Co. Ltd. (Tokyo:4568; Osaka:4568).